1. Market Research
  2. > Pharmaceutical Market Trends
  3. > PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies

PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies

Summary

The Global Pharmaceutical Market Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 30 leading drug companies on 25 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure, and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData’s Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report discusses trends impacting the pharmaceutical marketplace including FDA approvals, patent/generic erosion, regulatory changes, and the impact of the ACA on Rx, along with partnering and acquisition activity, and operations strategy. The report also provides a drill-down analysis identifying the revenue and growth leaders across 4 geographic regions (US, EU, Japan/Asia, and Emerging markets), and 11 therapeutic franchises. Lastly, this report provides GlobalData’s outlook on the Global Pharmaceutical market, and each company’s future competitive position including six-year forecasts for all 30 companies covered in the report.

Highlights

About the Report

GlobalData identified these 30 leading drug companies to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. GlobalData’s coverage examines these companies from a unique company-centric lens - combining financial performance and resources allocation with partnering activity and regional developments to assess a company’s overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies’ corporate growth.

Key Questions Answered

- What specific strategies are these drug companies employing to gain market share?
- What drivers accounted for the revenue growth for the company over the past year?
- Which trends will affect the global pharmaceutical market over the next few years?
- Who are the revenue and growth leaders in each therapeutic and geographical area?
- What specific business development activities are taking place, in terms of partnerships or M&A?
- What are the top-selling drugs in each therapeutic franchise and what are their sales forecasts through 2019?

Scope

- This report provides analysis of the key drivers and trends shaping the global pharmaceutical market; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation
- This report offers a deep dive into the synergies behind partnering and acquisition activity
- Covers 11 therapeutic franchises; market sizing, growth rates, company share, sales drivers of top drugs, pipeline movements, sales forecasts and product NPVs
- Assessments of company financials by revenue, margin, expense and capital structure
- Revenue and growth leaders across 4 geographies; US, EU, Japan/Asia, Emerging markets
- Firm utilization, efficiency metrics, capital ratios, headcount analytics

Reasons to buy

- Analyze and track the strategies that these drug companies are using to gain share in the increasingly competitive market
- Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
- Identifies the important disease areas, types of products, and geographical areas where companies are expanding to ensure their future success
- Independent source to benchmark your company’s performance against a similar peer group to assess areas of strength/weakness

Table Of Contents

PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies
1 Table of Contents

2 Introduction 25
2.1 Report Scope 25
2.1.1 Company Covereage 26
2.1.2 Therapy Franchise Coverage 26
2.2 Upcoming Reports 27
2.3 Recently Published Reports 27
2.4 GlobalData's Benchmarking Methodology 27
2.5 Benchmark Leader: Pfizer 28
3 Global Pharmaceutical Market Dynamics 31
3.1 Sector Overview 32
3.1.1 Peer Group Growth Rate 32
3.1.2 Peer Group RandD Spending 33
3.2 Corporate Valuations 34
3.2.1 Market Capitalization 34
3.2.2 Top 30 Pharma Valuations Compared Against the SandP500 36
3.3 FDA Approved 27 Novel New Drugs in 2013 37
3.3.1 From 2004 through 2013, CDER has Averaged 26 NME Approvals per Year 38
3.3.2 Multiple Pathways for Accelerating Drug Approvals 39
3.3.3 CDER Met or Exceeded PDUFA Goal Dates for All 27 NMEs Approved in 2013 41
3.3.4 Drug Approvals Signify a Commercial Focus on High Growth Therapeutic Areas 42
3.3.5 List of Approved NMEs in 2013 43
3.3.6 GlobalData Sales Forecast for 2013 Approved Drugs 45
3.4 New Approvals Drive Much Needed Value in the Pharmaceutical Market 46
3.4.1 Exceptional Uptake of Sovaldi and Tecfidera Paves the way for New Optimism in Pharma 48
3.5 Patent Cliff to Erode $65B in Sales by 2019 52
3.5.1 Top 50 Patent Expiries 53
3.6 Orphan Drugs: No Longer a Rare Opportunity 56
3.7 Regulatory Notes 59
3.7.1 FDA Issues Draft Guidance on Determination of Product Exclusivity for Biologics 59
3.7.2 Federal Appeals Court Rules FDA Has Authority to Regulate Stem Cells 60
4 Collaboration and Acquisition Strategies 62
4.1 Deal Values Soar Due to Shire Acquisition 62
4.2 Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms 68
4.2.1 Deal Terms 68
4.2.2 Combined Entity Holds Promise for AbbVie 68
4.2.3 Tax Inversion Impact on Humira Cash Flow 70
4.2.4 Shire Purchase Softens the Impact of AbbVie's Maturing Portfolio 71
4.2.5 Acquisition Reduces AbbVie's Dependency on Humira Sales 72
4.2.6 Shire Sales Forecasts and Portfolio Valuation 75
4.3 MandA Analysis 78
4.3.1 Roche Makes Respiratory Play with InterMune Buy 78
4.3.2 AstraZeneca Rejects Pfizer's Takeover Bid 80
4.3.3 Teva Acquires Novel Migraine Prophylaxis Treatment 81
4.3.4 Valeant's Business Model Not Conducive for Allergan 82
4.3.5 Shire Boosts Rare Disease Pipeline 83
4.3.6 BMS Acquires Neuro Firm iPierian 84
4.3.7 Amgen Dives into Multiple Myeloma Market, Gains Rights to Kyprolis 84
4.3.8 Bayer Buys-Out Cancer Partner Algeta, Purchases Conceptus 85
4.3.9 AZ Strengthens Respiratory Portfolio 85
4.3.10 JandJ Pays Big for Aragon's Lead Pipeline Candidate 86
4.3.11 Allergan Enhances Leadership Position in Neurology 87
4.3.12 Astex Deal Might Stem the Bleeding for Otsuka 87
4.3.13 Select Generic MandAs 87
4.4 Licensing and Partnerships 94
4.4.1 BMS on a Shopping Spree for Cancer Immunotherapies 94
4.4.2 Bayer Scoops-Up Orion's Phase III Prostate Cancer Drug 96
4.4.3 GSK Signs Deal with Adaptimmune to Develop T-cells 96
4.4.4 Celgene: A Licensing Machine 97
4.4.5 Novartis Pens Deal for Ophthotech's Wet-AMD Treatment Fovista 99
4.4.6 Merck Inks Potential Mega Deal with Ablynx, Sells-Off Eye Drugs 100
4.4.7 Biogen Forges Preclinical Alzheimer's Pact with Proteostasis 102
4.4.8 Roche Turns on the Switch in Epigenetics 102
5 Financial Management 104
5.1 Global Pharmaceutical Market Competitive Landscape Assessment 104
5.1.1 The Drug Sector Began to Show Signs of Stabilization in 2013 104
5.2 Financial Management: Heat Map 106
5.2.1 Gilead was the Financial Management Leader in 2013 106
5.3 Financial Performance Metrics 109
5.3.1 Revenue 109
5.3.2 Revenue Growth YtY 111
5.3.3 Operating Income 113
5.3.4 Operating Income Growth YtY 115
5.3.5 Operating Margin 117
5.3.6 Operating Income per FTE 119
5.3.7 Net Margin 121
6 Expense Management 123
6.1 Global Pharmaceutical Market Competitive Landscape Assessment 123
6.1.1 Consistent Cost Structures Give Drugmakers Margin Stability 123
6.1.2 Eisai Pushes Arena's Belviq with More Reps and Ad Spending 125
6.2 Expense Management: Heat Map 125
6.2.1 Eisai was the Expense Management Leader in 2013 125
6.3 Expense Performance Metrics 128
6.3.1 S,GandA Spending 128
6.3.2 S,GandA Spending as a Percentage of Revenue 130
6.3.3 SandM Spending 132
6.3.4 RandD Spending 133
6.3.5 RandD Spending Growth 136
6.3.6 RandD Spending as a Percentage of Revenue 138
7 Therapy Franchise Analysis 141
7.1 Cardiovascular 144
7.1.1 Commercial Landscape 144
7.1.2 Pipeline Highlights 151
7.2 CNS 155
7.2.1 Commercial Landscape 155
7.2.2 Pipeline Highlights 162
7.3 Diabetes 166
7.3.1 Commercial Landscape 166
7.3.2 Pipeline Highlights 171
7.4 Gastrointestinal 174
7.4.1 Commercial Landscape 174
7.4.2 Pipeline Highlights 179
7.5 Hematology 180
7.5.1 Commercial Landscape 180
7.5.2 Pipeline Highlights 184
7.6 Immunology 187
7.6.1 Commercial Landscape 187
7.6.2 Pipeline Highlights 193
7.7 Infectious Disease 200
7.7.1 Commercial Landscape 200
7.7.2 Pipeline Highlights 207
7.8 Oncology 208
7.8.1 Commercial Landscape 208
7.8.2 Pipeline Highlights 215
7.9 Ophthalmology 223
7.9.1 Commercial Landscape 223
7.9.2 Pipeline Highlights 232
7.10 Respiratory 236
7.10.1 Commercial Landscape 236
7.10.2 Pipeline Highlights 241
7.11 Vaccines 246
7.11.1 Commercial Landscape 246
7.11.2 Pipeline Highlights 252
8 Regional Analysis 257
8.1 North America Landscape Assessment 257
8.1.1 Growth Driven by Biotechs and Specialty Pharma 257
8.2 Regional Developments 260
8.2.1 Gilead's Price of Sovaldi May be a Pill too Tough to Swallow 260
8.2.2 States' Take Efforts into Their Own Hands to Limit the Influx of Opioids 260
8.3 Revenue and Growth Leaders 261
8.3.1 Revenue 261
8.3.2 Revenue Growth YtY 263
8.4 Europe Landscape Assessment 264
8.4.1 AstraZeneca Pulls Down EU Market 264
8.5 Regional Developments 267
8.5.1 Merck KGaA Targets Italian Production Site for Investment 267
8.5.2 Pfizer Partners with UK Academics to Develop Rare Disease Drugs 268
8.5.3 Bayer's Eylea Hits Road Block in Germany 268
8.6 Revenue and Growth Leaders 269
8.6.1 Revenue 269
8.6.2 Revenue Growth YtY 271
8.7 Asia-Pacific Landscape Assessment 272
8.7.1 Astellas Pharma was the Growth Leader in Asia 272
8.8 Regional Developments 274
8.8.1 China Targets Big Pharma in Corruption Investigation 274
8.8.2 UCB Secures Asian Marketing Rights to Biogen's MS Drugs 275
8.8.3 Merck KGaA Targets China with Allergy and Diabetes Plants 275
8.9 Revenue and Growth Leaders 276
8.9.1 Revenue 276
8.9.2 Revenue Growth YtY 277
8.10 Japan Landscape Assessment 278
8.10.1 Daiichi Sankyo Trumps its Domestic Rivals 278
8.11 Revenue and Growth Leaders 280
8.11.1 Revenue 280
8.11.2 Revenue Growth YtY 281
8.12 Emerging Markets Landscape Assessment 283
8.12.1 Differences in Regulatory and Commercialization Pathways Makes BRICs More Difficult than Previously Thought 283
8.13 Regional Developments 285
8.13.1 India to Receive Deep Discount on Sovaldi Price 285
8.13.2 Pharma Furious Over Compulsory Licensing in India 286
8.13.3 India Commits $500M to Doubling its Regulatory Force 287
8.13.4 Abbott Grows Footprint in Latin America with CFR Buy 287
8.13.5 GSK to Freeze Vaccine Prices for Developing Countries 287
8.13.6 Drug Manufacturers Look to the Middle East for Untapped Opportunities 288
8.14 Revenue and Growth Leaders 288
8.14.1 Revenue 288
8.14.2 Revenue Growth YtY 290
9 Resource Management Strategies 292
9.1 Human Capital Management 293
9.1.1 Headcount Analysis 293
9.1.2 Layoffs in 2013 297
9.2 Drugmakers Expand Manufacturing Capacity for Biologics 297
9.2.1 Roche Ramps up Production in Switzerland 297
9.2.2 Drugmakers Advance into Asia to Grab Share 298
9.2.3 Eisai Plans Major Sales Push in Russian Market 300
9.2.4 Daiichi Unloads Ranbaxy Problems to Sun Pharma 300
9.3 Firm Utilization: Heat Map 301
9.3.1 Pfizer was the Firm Utilization Leader in 2013 301
9.4 Firm Utilization Metrics 304
9.4.1 Headcount Growth YtY 304
9.4.2 Revenue per Employee 305
9.4.3 RandD Expense per RandD Employee 307
9.4.4 GandA Expense per GandA Employee 309
9.4.5 SandM Expense per SandM Employee 311
9.5 Capital Management: Heat Map 312
9.5.1 Allergan was the Capital Management Leader due to its Higher Liquidity 312
9.6 Capital Structure Metrics 313
9.6.1 Debt/Equity 313
9.6.2 Sales/Assets 315
9.6.3 Return on Capital Employed 316
9.6.4 Cash Ratio 318
9.6.5 Current Ratio 319
9.6.6 Quick Ratio 320
10 Future Outlook 322
10.1 Global Pharmaceutical Market 323
10.2 Company Forecasts 328
11 Market Data 330
11.1 Global Pharmaceutical Market 330
11.1.1 Pharmaceutical Revenue Forecast for 128 Leading Companies 330
11.2 Pipeline Analysis 333
11.2.1 Forecasts and Valuations 333
11.3 Company Pipeline Profiles 336
11.4 Molecule Type 367
11.4.1 Biologics Versus Small Molecules 367
12 Appendix 372
12.1 Research Methodology 372
12.1.1 Coverage 372
12.1.2 Secondary Research 372
12.2 About the Author 373
12.2.1 Adam Dion, Industry Analyst 373
12.3 Director, Healthcare Industry Dynamics 374
12.4 Global Head of Healthcare 374
12.5 About the Industry Dynamics Team 374
12.6 About GlobalData 375
12.7 Disclosure Information 375
12.8 Disclaimer 375

1.1 List of Tables
Table 1: GlobalData Benchmark Rankings, Global Pharmaceutical Market, 2013 29
Table 2: GlobalData Benchmark Rankings (cont'd), Global Pharmaceutical Market, 2013 30
Table 3: List of Approved New Molecular Entities, 2013 43
Table 4: Sales Forecast ($m) for Recently Approved Drugs, 2013 45
Table 5: Top 50 Patent Expiries, Sales ($m), 2013-2019 53
Table 6: Financial Management Composite Scores, 2013 107
Table 7: Expense Management Composite Scores, S,GandA, 2013 126
Table 8: Expense Management Composite Scores, RandD, 2013 127
Table 9: Therapy Franchise Market Outlook ($m) and Compound Annual Growth Rate, 2010-2019 143
Table 10: Top Largest Layoffs, 2013 297
Table 11: Firm Utilization Composite Scores, 2013 302
Table 12: Firm Utilization Composite Scores (cont'd), 2013 303
Table 13: Capital Management Composite Scores, Debt and Profitability Ratios, 2013 312
Table 14: Capital Management Composite Scores, Debt and Profitability Ratios, 2013 313
Table 15: Capital Management Composite Scores, Liquidity Ratios, 2013 317
Table 16: Capital Management Composite Scores, Liquidity Ratios, 2013 318

1.2 List of Figures
Figure 1: Combined Peer Group Revenue ($m) and Average Operating Margin, 2010-2013 32
Figure 2: Combined Peer Group RandD Spend ($m), 2010-2013 33
Figure 3: Total Market Capitalization ($bn), 2010-2014 34
Figure 4: Market Capitalization ($bn) by Company, 2014 35
Figure 5: Change in Market Capitalization ($bn) by Company 36
Figure 6: Top 30 Pharmaceutical Companies Valuation vs. SandP500 37
Figure 7: Number of NME Approvals and Applications Filed, 2004-2013 38
Figure 8: Percentage of NMEs by Approval Pathway, 2011-2013 40
Figure 9: Percentage of NMEs Approved First in the US and on First Cycle of Review, 2011-2013 41
Figure 10: Combined Revenue Projections of 2013 FDA Approvals vs. 2012 FDA Approvals ($m), 2012-2019 47
Figure 11: First Full-Year Sales ($m) of Major Product Launches by Year, 2009-2013 48
Figure 12: Revenue Projections for 2013 FDA Approvals ($m), 2013-2019 49
Figure 13: Patent Cliff Sales ($m) Erosion, 2013-2019 52
Figure 14: Percentage of Biosimilar Exposure on Company Revenues, 2013 55
Figure 15: Orphan Peer Group ($m) and Compound Annual Growth Rate, 2010-2019 57
Figure 16: Leading Orphan Drug Sales ($m), 2013 vs. 2019 58
Figure 17: Global Pharmaceutical Market, Total Deals and Deal Values ($m), 2009-2014 63
Figure 18: Number of MandA Deals and Deal Values ($m), 2009-2014 64
Figure 19: Number of Licensing Deals and Deal Values ($m), 2009-2014 65
Figure 20: MandA Deal Values ($m) by Company, 2004-2014 66
Figure 21: Licensing Deal Values ($m) by Company, 2004-2014 67
Figure 22: Projected Total Revenues ($m) for AbbVie/Shire Merger, 2014-2019 69
Figure 23: Tax Savings Impact of Shire Merger on Humira Cash Flow ($m), 2014-2029 71
Figure 24: Humira as a Percentage (%) of Total Sales Pre-and Post-Acquisition of Shire, 2014-2019 73
Figure 25: Potential Threat of Biosimilars on Humira Cash Flow ($m), 2014-2029 74
Figure 26: Combined Six-Year Forecast Revenues ($m) Across Shire's Portfolio 76
Figure 27: Shire Leading Assets by Net Present Value ($m) 77
Figure 28: InterMune, Esbriet, Sales Forecast ($m), 2013-2019 79
Figure 29: Global Pharmaceutical Market Landscape Assessment - FY2013 Revenue Growth vs. Operating Margin 106
Figure 30: Revenue ($m) by Company, 2013 110
Figure 31: Revenue Growth by Company, 2013 112
Figure 32: Operating Income ($m) by Company, 2013 114
Figure 33: Operating Income Growth by Company, 2013 116
Figure 34: Operating Margin by Company, 2013 118
Figure 35: Operating Income per Employee, 2013 120
Figure 36: Net Margin by Company, 2013 122
Figure 37: Global Pharmaceutical Market Landscape Assessment - FY2013 S,GandA Expense vs. RandD Expense 124
Figure 38: S,GandA Spending ($m) by Company, 2013 129
Figure 39: S,GandA Spend as a Percentage of Revenue by Company, 2013 131
Figure 40: Sales and Marketing Spending ($m) by Company, 2013 133
Figure 41: RandD Spending ($m) by Company, 2013 135
Figure 42: RandD Spending Growth by Company, 2013 137
Figure 43: RandD Spending as a Percentage of Revenue by Company, 2013 139
Figure 44: Peer Group Rx Sales ($m) and Compound Annual Growth Rate, 2010-2019 144
Figure 45: Cardiovascular Market Size ($m) and Compound Annual Growth Rate, 2010-2019 145
Figure 46: Cardiovascular Market Share, 2013 146
Figure 47: Cardiovascular Market Share, 2010 147
Figure 48: Cardiovascular Drug Sales ($m), 2013 vs. 2019 148
Figure 49: CNS Market Size ($m) and Compound Annual Growth Rate, 2010-2019 156
Figure 50: CNS Market Share, 2013 157
Figure 51: CNS Market Share, 2010 158
Figure 52: CNS Drug Sales ($m), 2006-2019 159
Figure 53: CNS Drug Sales ($m), 2013 vs. 2019 160
Figure 54: Diabetes Market Size ($m) and Compound Annual Growth Rate, 2010-2019 167
Figure 55: Diabetes Market Share, 2013 168
Figure 56: Diabetes Market Share, 2010 169
Figure 57: Diabetes Drug Sales ($m), 2013 vs. 2019 170
Figure 58: Gastrointestinal Market Size ($m) and Compound Annual Growth Rate, 2010-2019 175
Figure 59: Gastrointestinal Market Share, 2013 176
Figure 60: Gastrointestinal Market Share, 2010 177
Figure 61: Gastrointestinal Drug Sales ($m), 2013 vs. 2019 178
Figure 62: Hematology Market Size ($m) and Compound Annual Growth Rate, 2010-2019 181
Figure 63: Hematology Market Share, 2013 182
Figure 64: Hematology Market Share, 2010 183
Figure 65: Hematology Drug Sales ($m), 2013 vs. 2019 184
Figure 66: Immunology Market Size ($m) and Compound Annual Growth Rate, 2010-2019 188
Figure 67: Immunology Market Share, 2013 189
Figure 68: Immunology Market Share, 2010 190
Figure 69: Immunology Drug Sales ($m), 2006-2019 191
Figure 70: Immunology Drug Sales ($m), 2013 vs. 2019 192
Figure 71: Infectious Diseases Market Size ($m) and Compound Annual Growth Rate, 2010-2019 201
Figure 72: Infectious Disease Market Share, 2013 203
Figure 73: Infectious Disease Market Share, 2010 204
Figure 74: Infectious Disease Drug Sales ($m), 2013 vs. 2019 206
Figure 75: Oncology Market Size ($m) and Compound Annual Growth Rate, 2010-2019 210
Figure 76: Oncology Market Share, 2013 211
Figure 77: Revlimid vs. MabThera/Rituxan Sales ($m), 2006-2019 212
Figure 78: Oncology Market Share, 2010 212
Figure 79: Oncology Drug Sales ($m), 2013 vs. 2019 215
Figure 80: Ophthalmology Market Size ($m) and Compound Annual Growth Rate, 2010-2019 225
Figure 81: Ophthalmology Market Share, 2013 226
Figure 82: Eylea vs. Lucentis Sales ($m), 2007-2019 227
Figure 83: Ophthalmology Market Share, 2010 228
Figure 84: Ophthalmology Drug Sales ($m), 2013 vs. 2019 230
Figure 85: Respiratory Market Size ($m) and Compound Annual Growth Rate, 2010-2019 237
Figure 86: Respiratory Market Share, 2013 238
Figure 87: Respiratory Market Share, 2010 239
Figure 88: Spiriva vs. Advair Sales ($m), 2006-2019 240
Figure 89: Respiratory Drug Sales ($m), 2013 vs. 2019 241
Figure 90: Vaccine Market Size ($m) and Compound Annual Growth Rate, 2010-2019 247
Figure 91: Vaccines Market Share, 2013 249
Figure 92: Vaccines Market Share, 2010 250
Figure 93: Vaccine Drug Sales ($m), 2013 vs. 2019 251
Figure 94: North America Landscape Assessment, 2013 258
Figure 95: North America Landscape Assessment (cont'd), 2013 259
Figure 96: North America Revenue ($m) by Company, 2013 262
Figure 97: North America Revenue Growth by Company, 2013 264
Figure 98: Europe Landscape Assessment, 2013 266
Figure 99: Europe Landscape Assessment (cont'd), 2013 267
Figure 100: Europe Revenue ($m) by Company, 2013 270
Figure 101: Europe Revenue Growth by Company, 2013 272
Figure 102: APAC Landscape Assessment, 2013 273
Figure 103: APAC Landscape Assessment (cont'd), 2013 274
Figure 104: APAC Revenue ($m) by Company, 2013 277
Figure 105: APAC Revenue Growth by Company, 2013 278
Figure 106: Japan Landscape Assessment, 2013 279
Figure 107: Japan Revenue ($m) by Company, 2013 281
Figure 108: Japan Revenue Growth by Company, 2013 282
Figure 109: Emerging Markets Landscape Assessment, 2013 284
Figure 110: Emerging Markets Landscape Assessment (cont'd), 2013 285
Figure 111: Emerging Markets Revenue ($m) by Company, 2013 290
Figure 112: Emerging Markets Revenue Growth by Company, 2013 291
Figure 113: Peer Group Headcount, Total, 2010-2013 293
Figure 114: Headcount by Company, 2013 vs. 2012 294
Figure 115: Peer Group Headcount, RandD, 2010-2013 295
Figure 116: RandD Headcount by Company, 2013 vs. 2012 296
Figure 117: Headcount Growth by Company, 2013 305
Figure 118: Revenue per Employee (In $ Thousands) by Company, 2013 306
Figure 119: RandD Expense per RandD Employee (In $ Thousands) by Company, 2013 308
Figure 120: GandA Expense per GandA Employee (In $ Thousands) by Company, 2012 310
Figure 121: SandM Expense per SandM Employee (In $ Thousands) by Company, 2013 311
Figure 122: Debt to Equity Ratio by Company, 2013 314
Figure 123: Sales to Assets Ratio by Company, 2013 315
Figure 124: Return on Capital Employed Ratio by Company, 2013 316
Figure 125: Cash Ratio by Company, 2013 319
Figure 126: Current Ratio by Company, 2013 320
Figure 127: Quick Ratio by Company, 2013 321
Figure 128: Pharmaceutical Benchmark Peer Group, Global Market Forecast, ($m), 2013-2019 324
Figure 129: Pharmaceutical Revenue Forecast ($m) by Peer Group, 2013 vs. 2019 325
Figure 130: Marketed and Pipeline Sales ($m) by Company, 2013 326
Figure 131: Percentage of Total Revenues, Pharma vs. Non-Pharma, 2013 327
Figure 132: Total Revenue ($m) Forecasts by Company, 2013 vs. 2019 328
Figure 133: Prescription Drug Sales ($m) Forecasts by Company, 2013 vs. 2019 329
Figure 134: Global Pharmaceutical Market Forecast ($m), 2013-2019 331
Figure 135: Marketed Product and Pipeline Sales Contributions ($m), 2019 332
Figure 136: Total Pharmaceutical Pipeline Revenue ($m), 2013-2019 333
Figure 137: Marketed vs. Pipeline Sales Contribution ($m), 2019 334
Figure 138: Pipeline Net Present Value ($m) by Company 335
Figure 139: Pipeline Sales ($m) by Company, 2019 336
Figure 140: AbbVie, Number of Clinical Trials, Phase and Therapy Area, 2014 337
Figure 141: Allergan, Number of Clinical Trials, Phase and Therapy Area, 2014 338
Figure 142: Amgen, Number of Clinical Trials, Phase and Therapy Area, 2014 339
Figure 143: Astellas, Number of Clinical Trials, Phase and Therapy Area, 2014 340
Figure 144: AstraZeneca, Number of Clinical Trials, Phase and Therapy Area, 2014 341
Figure 145: Baxter, Number of Clinical Trials, Phase and Therapy Area, 2014 342
Figure 146: Bayer, Number of Clinical Trials, Phase and Therapy Area, 2014 343
Figure 147: Biogen Idec, Number of Clinical Trials, Phase and Therapy Area, 2014 344
Figure 148: Boehringer Ingelheim, Number of Clinical Trials, Phase and Therapy Area, 2014 345
Figure 149: BMS, Number of Clinical Trials, Phase and Therapy Area, 2014 346
Figure 150: Celgene, Number of Clinical Trials, Phase and Therapy Area, 2014 347
Figure 151: CSL, Number of Clinical Trials, Phase and Therapy Area, 2014 348
Figure 152: Daiichi Sankyo, Number of Clinical Trials, Phase and Therapy Area, 2014 349
Figure 153: Eisai, Number of Clinical Trials, Phase and Therapy Area, 2014 350
Figure 154: Eli Lilly, Number of Clinical Trials, Phase and Therapy Area, 2014 351
Figure 155: F. H. La-Roche, Number of Clinical Trials, Phase and Therapy Area, 2014 352
Figure 156: Gilead, Number of Clinical Trials, Phase and Therapy Area, 2014 353
Figure 157: GSK, Number of Clinical Trials, Phase and Therapy Area, 2014 354
Figure 158: Johnson and Johnson, Number of Clinical Trials, Phase and Therapy Area, 2014 355
Figure 159: Merck, Number of Clinical Trials, Phase and Therapy Area, 2014 356
Figure 160: Merck KGaA, Number of Clinical Trials, Phase and Therapy Area, 2014 357
Figure 161: Novartis, Number of Clinical Trials, Phase and Therapy Area, 2014 358
Figure 162: Novo Nordisk, Number of Clinical Trials, Phase and Therapy Area, 2014 359
Figure 163: Otsuka, Number of Clinical Trials, Phase and Therapy Area, 2014 360
Figure 164: Pfizer, Number of Clinical Trials, Phase and Therapy Area, 2014 361
Figure 165: Sanofi, Number of Clinical Trials, Phase and Therapy Area, 2014 362
Figure 166: Shire, Number of Clinical Trials, Phase and Therapy Area, 2014 363
Figure 167: Takeda, Number of Clinical Trials, Phase and Therapy Area, 2014 364
Figure 168: Teva, Number of Clinical Trials, Phase and Therapy Area, 2014 365
Figure 169: UCB Pharma, Number of Clinical Trials, Phase and Therapy Area, 2014 366
Figure 170: Revenue Forecast ($m) by Molecule Type, Small Molecule vs. Biologics, 2019 367
Figure 171: Biologics Sales ($m) by Company, 2013 368
Figure 172: Percentage of Total Revenues, Biologics vs. Small Molecules, 2013 369
Figure 173: Biologics and Small Molecule Sales ($m) by Company, 2013 370
Figure 174: Net Present Value of Biologics Portfolio ($m) by Company, 2013 371

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.